| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2022: ¥520,000 (Direct Cost: ¥400,000、Indirect Cost: ¥120,000)
Fiscal Year 2021: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2020: ¥520,000 (Direct Cost: ¥400,000、Indirect Cost: ¥120,000)
Fiscal Year 2019: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2018: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Outline of Final Research Achievements |
Systemic sclerosis (SSc) is known to be refractory disease due to fibrosis of the skin and internal organs. Although connective tissue growth factor (CTGF) has been well-documented in SSc fibrosis, CTGF has not been fully investigated. We studied the effects of Anti-CTGF antibody in SSc mice model. We examined pulmonary fibrosis and skin fibrosis in the mice model. Dermal sclerosis, pulmonary fibrosis and cytokine production were assessed. As for skin and pulmonary fibrosis in the topoisomeraseⅠ mice model, there were no statistically significant difference in the treatment with anti-CTGF antibody, but it had tendency to mitigate both fibrosis. In terms of fibrotic cytokine, SPP1 and α smooth muscle actin (ACTA2) had tendency to be reduced by treatment with anti-CTGF antibody. Anti-CTGF antibody may have anti-fibrotic effects in mice models of systemic sclerosis. Further researches are required to evaluate it.
|
